Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Government works at a snail's pace (pandemic or not). There will be a grant announcement upcoming. It's just too early right now. RBL's are in our corner and other studies are on-going.
I believe he said it was Labor Day weekend of 2018 that Leo was informed the deal came apart.
Good post! Amazing really that here we sit at such an anemically low market cap considering what seems like unlimited potential for a variety of conditions that B's 3 in 1 action can treat!
The beauty is we're just getting started.
Good luck all!
I think we could easily see a 20M or 30M volume day this week when you consider our market cap is only around $30M-$35M. It’s a total joke how cheap we are when you consider the vast potential of B not only for CV, but for multitudes of other multi billion dollar indications. We’re on the cusp of everyone waking up and realizing this fact.
I was sitting in the room several months back during the SH meeting when Leo stated we’ve recently learned more about B that makes our confidence level even higher in its potential.
Got to love your enthusiasm, but INO has 100M O/S, not 1B. Still, IPIX is the better positioned company to treat the effects of CV in perhaps a few short months from now, and not waiting for more than a year for vaccine to get approved.
Who cares... Did you sell your 1000 shares?
yes, this is the trial where Leo stated in the Grand Rapids meeting in which I attended where if any sign(s) of efficacy was shown, we (big pharma) will be knocking down your door for a deal.
Probably some very interested parties coming out of the SF conference. This is very good news this morning!!! I would expect news of a term sheet soon.
We need an OM deal soon and I’m hopeful that will be the case. I was at the Grand Rapids meeting and Leo indicated that we can’t expect a deal for the pill indication of B until some sort of efficacy is shown, so all the more important we get more money into the coffers for a PoC pill trial (assuming the safety trial goes well).
I would understand it differently that our partner for B OM would take care of all the details (including recruiting) for a phase 3 trial. Leo and Art were very pleased only 300 in the primary arm would be required. They made it clear they thought the number for B in phase 3 OM would be higher. They interpret this as the FDA would like to see an easier administered remedy to
Combat OM.
Hopeful there will be another very interested party willing to offer good terms for B OM. He (Leo) mentioned 3 times at least we had a deal last year until the new CEO in the partnering company pulled the plug. He strongly hinted the deal would have contained lucrative terms.
One would think others would be interested as well. I get the feeling it’s only a matter of
Time.
I would say Leo was a little measured in his tone in regards to the share price. He’s clearly a little frustrated and he should be. However, he was very enthusiastic when it
Came to discussing the prospects going forward with development. I think I mentioned yesterday that more recently gained information has heightened their already high expectations for Brilacidin. He didn’t discuss in any detail what gives them an even brighter outlook.
B for OM seemed to be mentioned a lot in the meeting both by Leo and Dr B. My hunch is they are actively working towards a B OM partnership.
Very detailed and thank you Yooper. It was nice meeting you at the meeting and hope you had a good drive home.
I think we were all very impressed by Art when he spoke. He seemed to exude a lot
Of confidence in the company. He definitely struck me as the type of guy that would have been long gone if he didn’t believe the company would ultimately have success.
Yes, I did attend and yes the word sachet came up on more than one occasion.
Yes, the company thought that was a huge positive that only 300 required for a P3 OM trial. Art was especially pleased to report this information.
That’s a good summary. Also, they are going
To change things up soon in an effort to draw more attention to the company and that might involve hiring a professional marketing company. News on that front soon per
Leo.
Also, they will not divulge the upfront from AS until they have to for strategic purposes. They feel they’re in a position of having higher leverage with potential suitors by withholding that information for now.
More info recently gained on B makes them more confident than ever in its ultimate success.
Amendment passed at the meeting. Now Q and A.
You’re such an eternal optimist!
No kidding and totally agree that people are going overboard looking for a better entry point. Seriously, we all knew the 10-Q wouldn’t contain anything of real significance. We’re close and i still believe the price was pushed up on Tuesday because somebody knows what’s upcoming. We have all these PR’s lately with big plans about implementing phase 3 and restarting oral UP and K. This can’t happen on our current budget, so I choose to believe the company has a large pharma hanging out there that is ready to ink a deal. Things take a lot longer than we all think.
Yeah, up 20% today. So much for the company funeral this week!!
We’re close folks to big news!
News tomorrow???
Only a matter of time before a deal is struck, and not a long time either!
Stay away for good now. You won’t be missed. Have a little class and decency by not announcing your flips. Nobody cares!
We all know the game you play and it's to create uncertainty.
Other more sensible investors believe with little doubt that B is a novel IP that belongs to IPIX, and others will not try to low-ball for fear of missing out. Sure, nobody wants to overpay, but big pharma also recognizes owning or partnering for B is a risk worth taking for a huge upside with blockbuster potential across multiple fronts.
The company is very confident and that makes me confident. We all know that can't go it alone at this stage, so a partnering opportunity I bet is soon upon us.
That's where you lose all credibility. Explain the reasons for measly $10M worth and why you don't think this indication is ripe for a partnership.
Folks, we're in the bullseye right now for partnership because B-OM is phase 3 approved. This is where the rubber meets the road.
It's easy to defend IPIX with B-OM phase 3 ready. The company has spent a million bucks on production of B and packaging for the trial. Global registrations in process. Don't listen to the dooms-day predictions.
Global pharmas have to be licking their chops to partner B and run the phase 3. This is easy picking, low-hanging fruit and doesn't get much better, swish and spit.. No approved alternative for prevention. Partner to be announced very soon!
Glad that's your call since the vast majority of your short term forecasts have been dead wrong! So we'll take that as a bullish signal, thank you.
Good post, thank you!
Agree, his message couldn't have meant anything else other than a partner is on board and especially so since it would be nearly impossible for the company to raise the money on their own to conduct a phase 3 OM trial.
To me it now makes sense why we had a delay in requesting the end of phase 2 meeting with the FDA. Time was needed to allow term sheet to be finalized and packaging to be complete.
It's going to be fun watching the stock movement leading up to the mid-December meeting and the anticipated news following.
We all know we're not going anywhere with OM phase 3 without a partnership. The company has spent approx $1M for B production and packaging in preparation for phase 3. I would think they have a plan in mind prior to committing to this kind of cash outlay.
Don't know up or down today, but I do know they have a plan for OM phase 3 if they've spend $1M towards manufacturing and packaging! Everyone knows a P3 OM trial is only possible through a partnership.
Come on, more likely they just need to develop the oral K and then partnering much more lucrative at that stage.
You can bet it's on-going. I think being vague is the best approach and not getting backed into a corner. I would not want the pharma behind the term sheet to use leverage against the company in the current negotiations based on Leo sending a definitive signal to investors.
Looks like liabilities from outside concerns only about 1.5M overall, so can't owe that much to CRO for P remaining balance.
Looks to me like the company will plan on licensing B OM separately and fund the other programs from the proceeds.
False Narrative. Just relax. You should be happy and especially so since you said they would never get a decent financing deal.
You wouldn't have any personal experience related to the "short and distort " section mentioned in the article, no way right??
Then why the call for 0.00 if you are not short? You know very well there are additional sources of financing available that have not been tapped into, and that almost all small bios have balance sheet issues.
What odds do you give a partnership for B materializing? I think it's practically a slam dunk if Leo isn't too greedy.
I.e. Help, I'm caught short!!
I hope that friend of yours is buying a lot more at this level!